Paul K. Wotton, Ph.D., has been named president and chief executive officer of Antares Pharma. Dr. Wotton previously served as president and chief operating officer, the titles he held upon joining the company in July 2008. Concurrently, Jack E. Stover has resigned as both chief executive officer and vice chairman of the board.

Dr. Wotton previously served as chief executive officer of Topigen Pharmaceuticals, following a stint as head of global business development at SkyePharma, as well as senior level positions at Eurand, Penwest Pharmaceuticals, Abbott, Merck, Sharp and Dohme.

Commenting on his new responsibilities, Dr. Wotton said, “I look forward to building shareholder value at Antares. The depth of our product pipelines in both our pharma and parenteral device divisions as well as our key partnership activities provide near and long-term growth opportunities for our business and share price.”